This article was originally published in The Rose Sheet
Executive SummaryFine fragrance revenue grew by double digits for the first nine months due to significant new launches and strong performance of specialty retail and direct-selling channels, Givaudan reports Oct. 9. Consumer Products business experienced high single-digit growth in local currencies with strong win rates achieved in hair care. Fragrance division sales fell 1.7% to $643.9 mil. (CH1=$.76). In local currencies, division sales were up 5.2%. Givaudan's net sales for the period grew 1.1% in Swiss Francs on a reported basis to $1.58 bil. Revenue was down 4.6% on a pro forma basis, assuming the acquisition of Nestle's flavor activities had taken place Jan. 1...
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.